Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Cash from Operations (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Cash from Operations for 16 consecutive years, with 6275000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 418.17% to 6275000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20775000.0 through Dec 2025, down 96.84% year-over-year, with the annual reading at 20775000.0 for FY2025, 96.84% down from the prior year.
  • Cash from Operations for Q4 2025 was 6275000.0 at Plus Therapeutics, down from 2530000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 1150000.0 in Q2 2024, with the low at 6275000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 3538705.88, with a median of 3006000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations soared 58.6% in 2024, then plummeted 418.17% in 2025.
  • Over 5 years, Cash from Operations stood at 3006000.0 in 2021, then increased by 25.68% to 2234000.0 in 2022, then increased by 15.8% to 1881000.0 in 2023, then soared by 35.62% to 1211000.0 in 2024, then tumbled by 418.17% to 6275000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 6275000.0, 2530000.0, and 5798000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.